Cancer Chemotherapy, Theoretical Foundations of
187
Akiyama, T., Yoshida, T., Tsujita, T., et al. (1997)
G1 phase accumulation induced by UCN-01
is associated with dephosphorylation of Rb
andCDK2p
ro
t
e
in
sa
sw
e
l
la
sindu
c
t
iono
f
CDK inhibitor p21/Cip1/WAF1/Sdl1 in p53-
mutated human epidermoid carcinoma A431
cells,
Cancer Res.
576
, 1495–1501.
An, W.G., Schulte, T.W., Neckers, L.M. (2000)
The
heat-shock
protein
90
antagonist
geldanamycin alters chaperone association
with p210bcr-abl and v-src proteins before
their degradation by the proteasome,
Cell
Growth Differ.
11
, 355–360.
Anderson, P.G.A. (2003) A Phase 2 study of
bortezomib in relapsed, refractory myeloma,
N. Engl. J. Med.
348
, 2609–2617.
Bandara, L.R., Girling, R., LaThangue, N.B.
(1997) Apoptosis induced in mammalian cells
by small peptides that functionally antagonise
the Rb-regulated E2F transcription factor,
Nat.
Biotech.
15
, 896–901.
Baselga, J. (2000) Continuous administration
of
ZD1839 (Iressa), a novel oral epider-
mal growth factor receptor tyrosine kinase
inhibitor, in patients with ±ve selected-tumour
types: evidence of activity and good tolerability,
Proc. Am. Soc. Oncol.
19
, 177a.
Baselga, J. (2001) The EGFR as a target for
anticancer therapy-focus on cetuximab,
Eur.
J. Cancer
37
, S16–S22.
Birner,
P.,
Schindl, M.,
Obermair, A.,
et al.
(2000) Over-expression of hypoxia-inducible
factor 1
α
is a marker for an unfavourable
prognosis
in
early-stage
invasive
cervical
cancer,
Cancer Res.
60
, 4693–4696.
Birner, P.,
Schindl, M.,
Obermair, A.,
Breite-
necker, G., Oberhuber, G. (2001a) Expression
of hypoxia-inducible factor 1
α
in epithelial
ovarian tumours: its impact on prognosis and
on response to chemotherapy,
Clin. Cancer
Res.
7
, 1661–1668.
Birner, P., Gatterbauer, B., Oberhuber, G., et al.
(2001b) Expression of hypoxia-inducible factor
1
α
in oligodendrogliomas: its impact on
prognosis and on neoangiogenesis,
Cancer
92
,
165–171.
Chan, H.-M., La Thangue, N.B. (2001) p300/CBP
proteins: HATS for transcriptional bridges and
scaffolds,
J. Cell Sci.
114
, 2363–2373.
Chiarle, R., Budel, L.M., Skolnik, J., et al. (2000)
Increased proteasome degradation of cyclin-
dependent kinase inhibitor p27 is associated
with a decreased overall survival in mantle cell
lymphoma,
Blood
95
, 619–626.
Ciardiello, F., Tortora, G. (2001) A novel approach
in the treatment of cancer: targeting the
epidermal growth factor receptor,
Clin. Cancer
Res.
7
, 2958–2970.
Connell, P., Ballinger, C.A., Jiang, J., et al. (2001)
The co-chaperone CHIP regulates protein
triage
decisions
mediated
by
heat-shock
proteins,
Nat. Cell Biol.
3
, 93–96.
Deininger, M.W.,
Goldman, J.M.,
Lydon, N.,
Melo, J.V. (1997) The tyrosine kinase inhibitor
CGP57148B selectively inhibits the growth of
BCR-ABL-positive cells,
Blood
90
, 3691–3698.
Deininger, M.W.,
Goldman, J.M.,
Melo, J.V.
(2000) The
molecular
biology
of
chronic
myeloid leukaemia,
Blood
96
, 3343–3356.
Druker, B.J., Lydon, N.B. (2000) Lessons learned
from the development of an abl tyrosine
inhibitor for chronic myelogenous leukaemia,
J. Clin. Invest.
105
, 3–7.
Dyson, N. (1998) The regulation of E2F by pRB-
family proteins,
Genes Dev.
12
, 2245–2262.
Feinman, R.,
Gangurde, P.,
Miller, S.,
et al.
(2001) Proteasome inhibitor PS-341 inhibits
constitutive NF-KB activation and bypass the
anti-apoptotic Bcl2 signal in human multiple
myeloman cells,
Blood
98
, 640a.
Foster, B.A. (1999) Pharmacological rescue of
mutant
p53
conformation
and
function,
Science
286
, 2507–2510.
Friedler, A.,
Hansson, L.O.,
Veprintsev, D.B.,
et al. (2002) A peptide that binds and stabilizes
p53 core domain: chaperone strategy for
rescue of oncogenic mutants,
Proc. Natl. Acad.
Sci. U.S.A.
99
, 937–942.
Gorre, M.E., Mohammed, M., Ellwood, K., et al.
(2001) Clinical resistance to STI-571 cancer
therapy caused by BCR-ABL gene mutation or
ampli±cation,
Science
293
, 876–880.
Hainaut, P. (2002) Tumour-speci±c mutations in
p53: the acid test,
Nat. Med.
8
, 21–23.
Hideshima, T.,
Richardson, P.,
Chauhan, D.,
et al. (2001) The proteasome inhibitor PS-
341 inhibits growth, induces apoptosis, and
overcomes drug resistance in human multiple
myeloma cells,
Cancer Res.
61
, 3071–3076.
Hochhaus, A., Kreil, S., Corbin, A., et al. (2001)
Roots of clinical resistance to ATI-571 cancer
therapy,
Science
293
, 2136.
Hockel, M., Vaupel, P. (2001) Tumour hypoxia:
de±nitions and current clinical, biologic, and
molecular aspects,
J. Natl. Cancer Inst.
93
,
266–276.
Hollstein
,M
.
, Hergennahn
,M
.
, Yang
,Q
. etal
.
(1999) New approaches to understanding p53
previous page 861 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online next page 863 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online Home Toggle text on/off